Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome

J Hepatol. 2007 May;46(5):935-46. doi: 10.1016/j.jhep.2007.02.001. Epub 2007 Feb 27.

Authors

Vicente Arroyo¹, Carlos Terra, Pere Ginès

Affiliation

¹ Liver Unit, Institute of Digestive and Metabolic Diseases, Hospital Clinic, University of Barcelona, Barcelona, Spain. varroyo@clinic.ub.es

PMID: 17391801
DOI: 10.1016/j.jhep.2007.02.001

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Adrenergic alpha-Agonists / therapeutic use
Ascites / complications
Cardiac Output, Low / complications
Cardiac Output, Low / physiopathology
Glomerular Filtration Rate
Hepatorenal Syndrome / classification
Hepatorenal Syndrome / complications
Hepatorenal Syndrome / physiopathology*
Hepatorenal Syndrome / therapy*
Hepatorenal Syndrome / urine
Humans
Kidney Function Tests
Liver Cirrhosis / complications
Liver Cirrhosis / physiopathology*
Liver Transplantation
Portasystemic Shunt, Transjugular Intrahepatic
Renal Circulation / drug effects
Renal Insufficiency / complications
Renal Insufficiency / physiopathology*
Splanchnic Circulation / drug effects
Vasoconstrictor Agents / therapeutic use
Vasodilator Agents / therapeutic use

Substances

Adrenergic alpha-Agonists
Vasoconstrictor Agents
Vasodilator Agents